Skip to main content
Equibles

Michael Tardugno

Chairman

Imunon, Inc. (IMNN)

CEO

Imunon, Inc. (IMNN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Imunon, Inc. publishes a filing, an earnings call transcript or a press release.

Get IMNN alerts

About Michael Tardugno

Michael Tardugno is recorded as Chairman and CEO at Imunon, Inc. (IMNN). The proxy statement of Imunon, Inc. reports total compensation of $605,899 for Michael Tardugno in fiscal 2025, including a base salary of $350,673. Disclosed compensation is on record for 7 fiscal years. Michael Tardugno has spoken on 14 earnings calls across 1 company, most recently for Imunon, Inc. on November 7, 2024. Imunon, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Imunon, Inc. includes Corinne Le Goff (CEO and Board Member), Stacy Lindborg (CEO and Board Member), Stacy R. Lindborg (CEO and Board Member) and 7 others.

Michael Tardugno on recent calls

“I don't have any questions but I do have just a short comment here. First, thanks for sharing a remarkable and very optimistic update.”
Chairman, Imunon, Inc. Q3 FY2024 Earnings Call ·
“I just wanted to take the liberty to say a few words before turning the call over to Stacy Lindborg, our President and Chief Executive Officer; and to David Gaiero, who is our Interim Chief Financial Officer, as we seek a permanent replacement for our retired CFO, Jeff Church.”
Chairman, Imunon, Inc. Q2 FY2024 Earnings Call ·
“Let me also thank you for joining us for this particularly important call. I want to start by welcoming Stacy Lindborg, your new Chief Executive and President, to her first call with the investment community and our supporters.”
Chairman, Imunon, Inc. Q1 FY2024 Earnings Call ·
“It's a pleasure to be here with you all. With me today are Jeffrey Church, our Chief Financial Officer, and Sebastien Hazard, our Chief Medical Officer. Dr. Hazard will discuss Imunon-001, IL-12 immunotherapy, and its expected role in treating advanced ovarian cancer.”
Chairman, Imunon, Inc. Q4 FY2023 Earnings Call ·
“I'm extraordinarily pleased to be here today with Dr. Corinne Le Goff, Celsion's new President and Chief Executive Officer. I'm also here with Jeffrey Church, our Chief Financial Officer; Dr. Nicholas Borys, our Chief Medical Officer; and Dr. Khursheed Anwer, our Chief Science Officer.”
Chairman, Imunon, Inc. Q2 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Imunon, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Imunon, Inc. (IMNN) $350,673 $605,899
2024 Imunon, Inc. (IMNN) $336,639 $734,810
2022 Imunon, Inc. (IMNN) $573,649 $2,085,391
2021 Imunon, Inc. (IMNN) $581,586 $2,312,625
2020 Imunon, Inc. (IMNN) $557,222 $1,429,073
2019 Imunon, Inc. (IMNN) $547,342 $1,251,640
2018 Imunon, Inc. (IMNN) $529,467 $2,950,091

Recent activity

Show 2 earlier activities